Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.
The SELECT Trial and Differentiated Thyroid Cancer
Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.
Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.
An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.
Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.
Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.